Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?
Given the high case fatality rate of SARS-CoV-2, for which there is no cure and no vaccine, clinicians are forced to make decisions about how best to manage patients with limited high-quality evidence to guide treatment. Traditional randomized controlled trials provide strong experimental evidence,...
Main Authors: | Westyn Branch-Elliman, Lisa Soleymani Lehmann, William E. Boden, Ryan Ferguson, Paul Monach |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Contemporary Clinical Trials Communications |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865420300983 |
Similar Items
-
Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial
by: Patricia Woods, et al.
Published: (2021-09-01) -
Embracing dynamic public health policy impacts in infectious diseases responses: leveraging implementation science to improve practice
by: Westyn Branch-Elliman, et al.
Published: (2023-08-01) -
Pandemic scientific data sharing recommendations: examining and re-imagining pre-print servers after the end of the world-wide emergency
by: Shira Doron, et al.
Published: (2023-01-01) -
Automating surveillance for healthcare-associated infections: Rationale and current realities (Part I/III)
by: Erica S. Shenoy, et al.
Published: (2023-01-01) -
Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation
by: Jennifer La, et al.
Published: (2022-12-01)